The Global Impact of Neurological Conditions

A recent Lancet study, highlighted by The Guardian, reveals how neurological conditions have become the leading cause of ill-health worldwide, with 11.1 million deaths in 2021.

In the past three decades we have seen an 18% spike in disability, illness and premature deaths attributable to 37 neurological conditions. This means neurological disorders affect an astonishing 43% of the global population, totaling 3.4 billion people. The hardest hit are low and middle income countries that experience a staggering 80% of neurological deaths and health loss.

Major contributors include stroke, dementia, and diabetes-related nerve damage. Researchers say this rise is linked to population growth, increased life expectancy, and exposure to environmental and lifestyle risk factors like pollution, obesity and diet.

This dramatic rise in neurological conditions underscores the urgent need for accessible and effective treatments, including new possibilities like ibogaine therapy.

The Rising Promise of Ibogaine in Neurological Treatments

Ibogaine and Veterans’ Traumatic Brain Injury Treatment

Ambio’s collaboration with Stanford University on the Magnesium–Ibogaine therapy study showcased significant improvements in veterans with TBI, addressing both functional impairments and psychiatric syndromes such as PTSD, depression, and anxiety.

This research leverages ibogaine’s unique properties, which interact with multiple neurotransmitter systems and stimulate neurotrophic factors vital for neuroregeneration.


Ibogaine and Neuropathic Pain Relief

Further strengthening the case for ibogaine’s versatility, a case report published in Frontiers in Pain Research, documents a breakthrough in treating severe neuropathic pain associated with brachial plexus nerve root avulsion. This success story adds a new dimension to ibogaine’s therapeutic potential, suggesting its efficacy in combating some of the most challenging neuropathic pain conditions.


Ibogaine and Addiction Treatment

In addition to pain research, ibogaine has been studied for its success rates in addiction treatments, where a MAPS-funded study of 30 subjects stands out. This research documented a significant reduction in opioid withdrawals, with 50% of subjects reporting no opioid use at 30 days post-treatment. There’s promise in easing withdrawal symptoms and also in facilitating long-term abstinence, albeit with outcomes heavily dependent on various factors.

To read more about this and other studies using ibogaine for addictions treatment, see our post.


Ibogaine and Parkinson’s Disease

Additionally, Ambio’s involvement in research exploring ibogaine’s role in treating Parkinson’s Disease shows the compound’s potential to reverse the effects of neurodegenerative disorders. This ongoing research, aiming to enhance GDNF production in the brain, could advance the treatment landscape for Parkinson’s, offering new hope to millions affected worldwide.

 

 

The Most Sophisticated Drug on the Planet

The study of ibogaine is complex and exciting. Ambio is not only advocating for ibogaine’s therapeutic applications but is actively contributing to a broader understanding and acceptance of its benefits across a range of neurological conditions.

Follow along as we continue this exploration in what Dr. Nolan Williams calls ‘the most sophisticated drug on the planet.’

Found what you’ve been looking for? Have more questions?

Please reach out, we are waiting for you.

Much love, the Ambio Team